Physician profile
Nisarg Desai
NPI 1174768956
$901.87
in general payments reported to CMS, 2019-2025
17 companies · $70.07 in 2025
The $70.07 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $65.18 · 2021: $144 · 2022: $163 · 2023: $135 · 2024: $103 · 2025: $70.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $188.52 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $140.00 | 2019-2021 | |
| Eisai INC. | $111.12 | 2022 | |
| Janssen Biotech, INC. | $96.71 | 2019 | |
| Rigel Pharmaceuticals, INC. | $82.27 | 2020-2024 | Tavalisse, Rezlidhia |
| Abbvie INC. | $62.44 | 2019-2025 | Lupron Depot |
| Exelixis INC. | $42.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $40.43 | 2019-2022 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Pfizer INC. | $19.88 | 2024 | |
| Genmab U.S., INC. | $17.09 | 2023 | Tivdak |
| Array Biopharma INC | $17.03 | 2024 | Lorbrena, Braftovi, Mektovi |
| Puma Biotechnology, INC. | $16.47 | 2024 | |
| Lilly USA, LLC | $15.11 | 2019 | |
| Emd Serono, INC. | $14.87 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $13.62 | 2023 | Imbruvica |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisarg Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.